Organization & Developments: Akebia

Parents

Akebia Therapeutics Inc. (NASDAQ: AKBA)*

Children

*Akebia also has a platform of novel HPTPß inhibitors / Angiopoietin 2 modulators which have demonstrated preclinical proof of concept in vascular leak, angiogenesis and as anti-metastatic agents.
*Development of small molecules for the treatment of anemia and vascular disease.
*The company’s lead compound, AKB-6548, is a once daily, oral HIF2 stabilizing agent (HIF-PH inhibitor) in phase 2 clinical trials for chronic anemia.
2016: Biotech Forum Daily Digest: Acadia, Collaboration Deals Boost Akebia And Conatus. Spotlight On Anika Therapeutics - iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)
2017: Revisiting Akebia Therapeutics - Akebia Therapeutics, Inc. (NASDAQ:AKBA)
2018: Akebia Therapeutics Is An Attractive Investment In 2018_seekingalpha.com
2019: Akebia_Lining Up Another Potential 50% Return _ gallery.mailchimp.com
2020: The Play On Akebia Now
2021: Akebia: Pessimism On Vadadustat Approval Justified, But Risky Bull Case Can Be Made
2021: Another Look At Akebia Therapeutics
2022: Akebia reveals sweeping layoffs and vadadustat partial clinical hold after FDA snub_ fiercepharma
2022: Safety concerns lead FDA to reject Akebia's kidney drug
2023: Akebia Therapeutics: Waiting For Round 2_seekingalpha.com
2024: Akebia Therapeutics: Generics Competition Means Rough Weather Ahead
2024: Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
2024: Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
2025: Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying
2025: Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026
2025: Akebia's Valuation Looks Stretched Despite Auryxia's Loss Of Exclusivity

Jumps

*Key People: Akebia
Finance & Acquisitions: Akebia

Made with TheBrain